Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

Integra LifeSciences was founded in 1989 and is headquartered in Princeton, New Jersey. The company went public on the Nasdaq in 1998 under the ticker IART. Its product portfolio spans neurosurgery, wound reconstruction and care, surgical reconstruction, surgical instrumentation and lighting, and ear, nose and throat (ENT) solutions (per the firm, 2026). The company's strategy centers on developing and acquiring medical devices and regenerative tissue products. Key asset classes include surgical instruments, neuro-critical care monitoring devices, wound dressings, and dural repair matrices. Confirmed product lines include the PriMatrix® dermal regeneration matrix and the Acellular® wound closure system. Integra has made multiple acquisitions to build its portfolio, including the purchase of the surgical instrument business from Becton Dickinson in 2018 (per SEC filings, 2018). Its geographic footprint covers the United States, Europe, Asia, and Latin America. Integra employs approximately 3,800 people globally. The company's products are used in over 60 countries. In 2025, Integra acquired the surgical instrument assets of Synovis Life Technologies to expand its microsurgery offerings (per the firm, 2025). The company also operates a philanthropy foundation, the Integra Foundation, which supports brain tumor research and other health initiatives. A structural differentiator is Integra's focus on regenerative medicine as a core pillar — a product category that typically requires FDA premarket approval and multi-year clinical data. This creates a high barrier to entry compared to a pure medical device manufacturer (per the firm, 2026).